Cancer prevention refers to measures that people can take to reduce their risk of developing cancer. These measures can include lifestyle changes, like eliminating tobacco use, maintaining a healthy weight, staying active, and limiting...
The spectacular sight of the AACR Annual Meeting 2019 Opening Ceremony, held Sunday, March 31, at the Georgia World Congress Center in Atlanta was immediately followed by a splendid opening plenary session, titled “Achieving...
Non-Hispanic black men in the United States are much more likely to develop prostate cancer and to die from the disease than their non-Hispanic white counterparts. Many factors contribute to this striking disparity, including...
Colorectal cancer is the second leading cause of cancer death in the United States. More than 50,000 people are estimated to have died from colorectal cancer in the United States last year, according to...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the first approval of an immunotherapeutic for use in the treatment of breast cancer.
Rates of diabetes in the United States are increasing. According to statistics from the Centers for Disease Control and Prevention (CDC), an estimated 23 million Americans received a diagnosis of diabetes in 2015, in...
The FDA approved a new molecularly targeted therapeutic for patients ages 2 or older who have been diagnosed with a rare type of blood cancer called blastic plasmacytoid dendritic cell neoplasm.
The FDA recently approved a new anticancer therapeutic for treating patients with childhood acute lymphoblastic leukemia (ALL).
Immune-related adverse events (irAEs) is the collective term used to describe the side effects that arise in response to activation of the immune system by immunotherapies. As this class of cancer treatment yields undisputed...
The FDA expanded the use of pembrolizumab to treat certain patients with a rare, aggressive type of skin cancer called Merkel cell carcinoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More